Global Health Limited is one of the largest private multi-speciality tertiary care providers operating in the North and East regions of India. The company has key specialities in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopaedics, liver transplant, and kidney and urology.
Global Health Limited have a network of four hospitals currently in operation (Gurugram, Indore, Ranchi and Lucknow) under the “Medanta” brand. The company established “The Medanta Institutional Tissue Repository” in 2017 to promote biomarker and other tissue-based research.
In Fiscals 2020, 2021 and 2022 and the three months ended June 30, 2021 and 2022, the company generated income from healthcare services of Rs. 14,805.71 million, Rs. 14,178.41 million, Rs. 21,003.95 million, Rs. 4,732.10 million and Rs. 5,960.89 226 million, respectively, and had EBITDA of Rs. 2,304.54 million, Rs. 2,228.52 million, Rs. 4,897.57 million, Rs. 1,057.69 million and Rs. 1,416.46 million, respectively.
As of June 30, 2022, the company provide healthcare services in over 30 medical specialities and engage over 1,300 doctors led by experienced department heads, spanning an area of 4.7 million sq. ft., the operational hospitals have 2,467 installed beds.
Global Health Limited’s hospital at Gurugram was ranked as the best private hospital in India for three consecutive years in 2020, 2021 and 2022, and was the only Indian private hospital to be featured in the list of top 200 global hospitals in 2021 and was featured in the list of top 250 global hospitals in 2022 by Newsweek
- Leading tertiary and quaternary care provider in India, well recognised for clinical expertise in particular in dealing with complicated cases.
- Focus on Clinical Research and Academics.
- Large-scale hospitals with world-class infrastructure, high-end medical equipment, and technology.
- Track record of strong operational and financial performance.
- Focus on under-served areas with dense population and presence in top or capital cities of large states (NCR, Lucknow and Patna).
- Growth opportunities in existing facilities and diversification into new services, including digital health.
- Experienced senior management team with strong institutional shareholder support.
|Period Ended||Total Assets||Total Revenue||Profit After Tax||Net Worth||Total Borrowing|
|Amount in ₹ Crore|
Objects of the Issue
The company proposes to utilize the net proceeds of the Fresh Issue towards funding of the following objects:
1. Repayment/prepayment of borrowings, in full or part, of the Subsidiaries, GHPPL and MHPL.
2. General corporate purposes.
Global Health IPO Details
|IPO Date||Nov 3, 2022 to Nov 7, 2022|
|Face Value||₹2 per share|
|Price||₹319 to ₹336 per share|
|Lot Size||44 Shares|
|Issue Size||[.] shares of ₹2|
(aggregating up to ₹2,205.57 Cr)
|Fresh Issue||[.] shares of ₹2|
(aggregating up to ₹500.00 Cr)
|Offer for Sale||50,761,000 shares of ₹2|
(aggregating up to ₹1,705.57 Cr)
|Issue Type||Book Built Issue IPO|
|Listing At||BSE, NSE|
|QIB Shares Offered||Not more than 50% of the Offer|
|NII (HNI) Shares Offered||Not less than 15% of the Offer|
|Retail Shares Offered||Not less than 35% of the Offer|
|Company Promoters||Dr. Naresh Trehan is the company promoter.|
Global Health IPO Tentative Timetable
Global Health IPO opens on Nov 3, 2022, and closes on Nov 7, 2022. The Global Health IPO bid date is from Nov 3, 2022 10.00 A.M. to Nov 7, 2022 5.00 P.M. The Cut-off time for UPI Mandate confirmation is 5 PM on the issue closing day.
|Opening Date||Nov 3, 2022|
|Closing Date||Nov 7, 2022|
|Basis of Allotment||Nov 11, 2022|
|Initiation of Refunds||Nov 14, 2022|
|Credit of Shares to Demat||Nov 15, 2022|
|Listing Date||Nov 16, 2022|
Global Health IPO Lot Size
The Global Health IPO lot size is 44 shares. A retail-individual investor can apply for up to 13 lots (572 shares or ₹192,192).
Global Health IPO Promoter Holding
|Pre Issue Share Holding||35%|
|Post Issue Share Holding||33%|
Global Health IPO Review
GHL is operating under the most popular healthcare brand “Medanta” and posted growth over the years in its scale of operations. The issue is attractively priced based on its financial data and well compares with listed peers. Investors may consider an investment with medium to long-term perspectives.
Company Contact Information
Global Health Limited
Medanta – Mediclinic,
E-18, Defence Colony,
New Delhi, Delhi 110 024,
Phone: +91 124 483 4060
Global Health IPO Registrar
KFin Technologies Limited
Phone: 04067162222, 04079611000